Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.

Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M.

Mol Cancer. 2014 Jun 4;13:141. doi: 10.1186/1476-4598-13-141.

2.

Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.

Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S.

J Thorac Oncol. 2012 Feb;7(2):272-80. doi: 10.1097/JTO.0b013e3182398e69.

3.

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.

Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.

4.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

5.

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.

J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.

PMID:
16106023
6.

The genomic landscape of response to EGFR blockade in colorectal cancer.

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.

Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.

7.

EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.

Ito Y, Yamada Y, Asada K, Ushijima T, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1391-6. doi: 10.1007/s00432-013-1454-9. Epub 2013 May 31.

PMID:
23722667
8.

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.

Eur J Cancer. 2013 Jul;49(10):2345-55. doi: 10.1016/j.ejca.2013.03.005. Epub 2013 Apr 8.

9.
10.

Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M.

Cancer Res. 2011 Dec 15;71(24):7587-96. doi: 10.1158/0008-5472.CAN-11-0821. Epub 2011 Oct 14.

11.

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR.

PLoS Genet. 2014 Mar 27;10(3):e1004271. doi: 10.1371/journal.pgen.1004271. eCollection 2014 Mar.

12.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
13.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

14.

Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.

Woo J, Palmisiano N, Tester W, Leighton JC Jr.

Cancer. 2013 Jun 1;119(11):1941-50. doi: 10.1002/cncr.27994. Epub 2013 Mar 15. Review.

15.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.

Cancer Cell. 2006 Jun;9(6):485-95. Epub 2006 May 25.

16.

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J.

Clin Cancer Res. 2014 Dec 15;20(24):6346-56. doi: 10.1158/1078-0432.CCR-14-0361. Epub 2014 Oct 16.

17.

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.

Juchum M, Günther M, Laufer SA.

Drug Resist Updat. 2015 May;20:12-28. doi: 10.1016/j.drup.2015.05.002. Epub 2015 May 12. Review.

PMID:
26021435
18.

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.

Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F.

Clin Cancer Res. 2013 Dec 15;19(24):6751-65. doi: 10.1158/1078-0432.CCR-13-0423. Epub 2013 Oct 11.

19.

[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].

Tímár J, Láng I.

Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7. Review. Hungarian.

PMID:
18640895

Supplemental Content

Support Center